Welcome to our dedicated page for Orchard Therapeutics Plc news (Ticker: ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orchard Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orchard Therapeutics Plc's position in the market.
Orchard Therapeutics, acquired by Kyowa Kirin, announced multiple presentations at the ASGCT 2024, showcasing HSC gene therapy for rare diseases. Data includes positive results for atidarsagene autotemcel, OTL-203 for MPS-IH, and OTL-104 for Crohn's disease. The presentations demonstrate the transformative impact of Orchard's approach and the potential of its pipeline.
Dr. Bobby Gaspar, co-founder and CEO of Orchard Therapeutics, has been named to the 2024 TIME100 Health list for his contributions to gene therapy. Orchard Therapeutics, now owned by Kyowa Kirin, aims to advance gene therapies globally. Dr. Gaspar's recognition highlights his significant impact on transforming treatment for genetic diseases, with key achievements in HSC gene therapy and regulatory approvals in Europe and the U.S.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.